Losartan for EB: First steps have been taken

For this project, Midas is acting as an industrial partner of the University Dermatology Clinic in Freiburg, the German centre for patients with Epidermolysis Bullosa (EB), a rare disease that occurs in newborns and causes great suffering for the young patients and their parents.

As sponsor for the pharmaceutical development of a paediatric dosage form of Losartan we will present a poster on the congress as co-authors.

Drug development requires a huge effort, even with an ‘easy’ development path. The first steps have been made. The project is advancing. But to reach maturity more capacity is needed and so the recruitment efforts for additional network partners are ongoing.

Funding is needed to conduct the Phase III clinical trial REFLECT 2 and to develop the respective study medication of losartan.

Further information about the project can be found in this exposé. Please feel free to contact us with any questions at any time.